title: [Therapy refractory stromal Herpes keratitis under aciclovir].
abstract: We report the case of a patient with suspected ulcerating necrotizing herpetic stromal keratitis who showed no improvement despite intensive (amongst others antiherpetic) topical and systemic therapy. The ulcer healed following amniotic membrane transplantation and penetrating excimer laser keratoplasty was performed to improve visual acuity. The excision showed deep stromal proof of herpes simplex virus (HSV) type 1 antigens.
authors.affiliation: Klinik für Augenheilkunde, Universitätsklinikum des Saarlandes UKS, Kirrberger Str. 100, Gebäude 22, 66424, Homburg/Saar, Deutschland, corinna.spira@uks.eu.
authors.forename: C
authors.initials: C
authors.lastname: Spira
authors.forename: N
authors.initials: N
authors.lastname: Szentmáry
authors.forename: A
authors.initials: A
authors.lastname: Hasenfus
authors.forename: M
authors.initials: M
authors.lastname: Sauter
authors.forename: S
authors.initials: S
authors.lastname: Smola
authors.forename: B
authors.initials: B
authors.lastname: Seitz
mesh_terms: D000212:Acyclovir / Q000627:therapeutic use*; D000368:Aged; D000650:Amnion / Q000637:transplantation*; D000998:Antiviral Agents / Q000627:therapeutic use; D001684:Biological Dressings; D003131:Combined Modality Therapy / Q000379:methods; D006801:Humans; D016849:Keratitis, Herpetic / Q000473:pathology* / Q000601:surgery*; D015948:Keratoplasty, Penetrating / Q000379:methods*; D053685:Laser Therapy / Q000379:methods*; D008297:Male; D017211:Treatment Failure; D016896:Treatment Outcome
chemical_list: D000998:Antiviral Agents; D000212:Acyclovir
references.citation: Ophthalmology. 2006 Nov;113(11):1927-35
references.pmid: 17074561
references.citation: Ophthalmology. 1990 Jun;97(6):722-8
references.pmid: 2165231
references.citation: J Clin Virol. 2003 Jan;26(1):29-37
references.pmid: 12589832
references.citation: Drug Dev Ind Pharm. 2013 Apr;39(4):508-19
references.pmid: 22424312
references.citation: Ophthalmology. 1999 Jun;106(6):1156-64; discussion 1165
references.pmid: 10366086
references.citation: Antimicrob Agents Chemother. 1995 Dec;39(12):2759-64
references.pmid: 8593015
references.citation: Klin Monbl Augenheilkd. 2008 Jan;225(1):75-9
references.pmid: 18236375
references.citation: Invest Ophthalmol Vis Sci. 2001 Aug;42(9):1969-74
references.pmid: 11481259
references.citation: Br J Ophthalmol. 2003 Oct;87(10):1215-9
references.pmid: 14507749
references.citation: Arch Ophthalmol. 2006 Oct;124(10):1487-90
references.pmid: 17030720
references.citation: Ophthalmologe. 2011 Apr;108(4):385-95; quiz 396-7
references.pmid: 21448683
references.citation: Klin Monbl Augenheilkd. 1976 Nov;169(5):584-90
references.pmid: 794567
references.citation: Klin Monbl Augenheilkd. 1985 Jun;186(6):421-3
references.pmid: 2413240
references.citation: Cornea. 1999 Mar;18(2):144-54
references.pmid: 10090359
references.citation: J Antimicrob Chemother. 2004 Jun;53(6):899-901
references.pmid: 15140857
references.citation: Klin Monbl Augenheilkd. 2010 May;227(5):388-92
references.pmid: 20490992
references.citation: J Pharmacol Exp Ther. 1998 Sep;286(3):1166-70
references.pmid: 9732374
references.citation: Ocul Immunol Inflamm. 2004 Dec;12(4):255-85
references.pmid: 15621867